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BACKGROUND: Considerable interest lies in the identification of novel anti-angiogenic compounds for cancer therapy. We have
investigated whether dexrazoxane has anti-angiogenic properties and if so, the mechanism of the inhibition.
METHODS: The phenotypic effects of dexrazoxane on endothelial cell behaviour was investigated both in vitro using human umbilical
vein endothelial cells (HUVECs) in cell proliferation, migration, cell cycle and aortic ring assays; and in vivo using the mouse
angiogenesis subcutaneous sponge assay. Custom angiogenesis pathway microarrays were used to identify differentially expressed
genes in endothelial cells after treatment with dexrazoxane vs a control. The differentially expressed genes were validated using real-
time RT–PCR and western blotting; and the functional effect of one induced gene was confirmed using siRNA technology.
RESULTS: Treatment of endothelial cells with dexrazoxane resulted in a dose–response inhibition of cell growth lasting for up to 5 days
after a single dose of the drug. Dexrazoxane was inhibitory in the aortic ring tube forming assay and strongly anti-angiogenic in vivo in
the rodent subcutaneous sponge model. The anti-angiogenic effect in the sponge was seen after systemic injection into the tail vein as
well as after direct injection of dexrazoxane into the sponge. Treatment of microvascular endothelial cells in vitro with subtoxic doses
of dexrazoxane stimulated thrombospondin-1 (THBS-1) secretion. Knockdown of THBS-1 with siRNA removed the angiogenesis
inhibition effect of dexrazoxane, which is consistent with the anti-angiogenic and vascular normalising properties of the drug being
principally mediated by THBS-1.
CONCLUSIONS: We show that dexrazoxane administered in small repeated doses is strongly anti-angiogenic and that this activity is
mediated by induction of the anti-angiogenic THBS-1 in endothelial cells.
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Recent studies have shown that anti-angiogenic agents are
more effective when given in combination with conventional
chemotherapeutic agents rather than as single agents and there
is much interest in the identification of novel anti-angiogenic
agents (Blumenschein, 2008). The bisdioxopiperazine drug,
razoxane (ICRF-159) was originally disclosed as an anti-cancer
agent in the 1960s (Herman et al, 1982). Razoxane is a racemic
drug, with the S-(þ)-enantiomer, dexrazoxane (ICRF-187,
Zinecard) being more water soluble (Supino, 1984). Early studies
with razoxane showed that the drug could inhibit metastasis
in the Lewis lung carcinoma model, where the treated tumours
had more ‘normalised’ blood vessels compared with the network
of poorly defined vascular channels found in control tumours
(Hellmann and Burrage, 1969; Salsbury et al, 1970, 1974; Le Serve
and Hellmann, 1972; Hellmann et al, 1974). Subsequent clinical
trials of razoxane demonstrated modest anti-tumour activity as a
single agent in head and neck carcinomas, acute leukemias,
lymphomas and advanced colorectal carcinomas (Gilbert, 1986;
Wexler, 1998).
Razoxane also demonstrated activity in combination with
radiotherapy against liver metastases from colorectal, inoperable
nonmetastatic rectal, bladder, vulval and lung carcinomas; soft
tissue and osteosarcomas; and central nervous system tumours
including malignant glioma and astrocytoma (Hellmann and
Rhomberg, 1991). However, the use of razoxane as an anti-cancer
agent was discontinued after a small increase in acute leukaemia
with prolonged use of 41 year. More recently, razoxane as an
orally administered single anti-angiogenic agent was demonstrated
in patients with inoperable renal cell cancer to be well tolerated
and resulted in acceptable response rates with very low toxicity
and minimal side effects, principally nausea and vomiting
(Braybrooke et al, 2000). Revised 24 June 2009; accepted 30 June 2009
*Correspondence: Professor R Bicknell, Institute for Biomedical Research,
Schools of Immunity and Infection and Cancer Studies, College of
Medicine and Dentistry, University of Birmingham, Vincent Drive,
Edgbaston, Birmingham B15 2TT, UK; E-mail: R.Bicknell@bham.ac.uk
British Journal of Cancer (2009) 101, 957–966
& 2009 Cancer Research UK All rights reserved 0007– 0920/09 $32.00
www.bjcancer.com
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sIn current clinical practice, dexrazoxane is used in adjuvant
therapy for cardioprotection during anthracycline therapy. It is
administered in 3 weekly cycles intravenously at a ratio of
multiples, for example, 10:1 to anthracycline dosage. At this
dosage, it has not been associated with an increased incidence of
secondary malignant neoplasms (Barry et al, 2008). It is also
currently the only antidote for accidental anthracycline extra-
vasation to prevent tissue necrosis (Langer et al, 2007).
Dexrazoxane has several biological modes of action. Firstly,
it undergoes full ring hydrolysis to form the EDTA analogue,
ADR-925, which acts as a chelating agent for divalent cations. The
clinical use of anthracyclines is limited by a cumulative
cardiotoxicity and this is thought to be due to iron-based oxygen
free radical induced oxidative stress on the heart muscle that is
low in anti-oxidant enzymes (Hasinoff et al, 1998). Chelation of
divalent cations is thought to be responsible for the clinical
effectiveness of dexrazoxane in reducing the cardiotoxicity of
doxorubicin and other anthracyclines. The cardioprotective effect
of dexrazoxane is due to blocking of the formation of these reactive
oxygen radicals by chelation of unbound transition metals (Huang
et al, 1982; Synold et al, 1998). Secondly, dexrazoxane, but not
ADR-925, displays strong DNA topoisomerase (topo) II inhibitory
activity (Hasinoff et al, 1995). The topo II inhibition exerted by
dexrazoxane is due to its binding and stabilisation of the protein/
DNA complex. This is distinct from etoposide, which acts by
inhibiting topo II mediated resealing of DNA strand breaks and
aclarubicin, which inhibits the binding of topo II to its DNA
substrate.
The anti-tumour activity of razoxane and dexrazoxane may
therefore be due to iron chelation (Creighton et al, 1969), inhibi-
tion of the enzymatic activity of topo II (Tanabe et al, 1991), a
combination of both or some other unknown mechanism.
It has recently been demonstrated that anti-angiogenic agents
are likely to work through a process of normalisation of vascula-
ture wherein leaky tortuous vessels in tumours are ‘normalised’
and excess vessels pruned, resulting in a reduction of interstitial
fluid pressure during a transient ‘normalisation window’ (Tong
et al, 2004; Willett et al, 2004). This normalisation of the tumour
vasculature increases blood flow and oxygen to the tumour.
Delivery of chemotherapeutic drugs during that window improves
cytotoxic drug delivery resulting in tumour response and
improved survival. Indeed, this is the mechanism of action of
‘Bevazicumab’ the first anti-angiogenic agent to show improve-
ment in survival in colorectal cancer when co-administered with
cytotoxic agents but has limited anti-tumour activity on its
own (Hurwitz et al, 2004). The early studies showing that
razoxane is anti-metastatic with accompanying normalisation
of blood vessels in tumours suggests that razoxane could
have anti-angiogenic properties, but to date this has not been
documented.
Given the interest in vascular normalising agents, we investi-
gated whether dexrazoxane was anti-angiogenic and whether the
anti-angiogenic properties of the drug could be explained by its
known modes of action or whether there existed some other as yet
undiscovered mechanism of action. We show that dexrazoxane
administered in small repeated doses is strongly anti-angiogenic
and that this activity is mediated by induction of the anti-
angiogenic THBS-1 in endothelial cells.
MATERIALS AND METHODS
Endothelial cell growth response curves and proliferation
assays
Human dermal microvascular endothelial cells (HDMECs,
Clonetics, San Diego, CA, USA) and human umbilical vein endo-
thelial cells (HUVECs)—isolated as per protocol (Jaffe et al, 1973)
were seeded either into six-well plates at 50000 cells per well and
into 96-well plates at 2000 cells per well and allowed to attach for
24h. The cells were treated with drug, and cell numbers were
counted after the desired incubation time using a Beckmann
Coulter counter. Additionally, cell numbers were determined by
MTS assay (Promega, Madison, WI, USA). Briefly, the MTS dye,
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxymethoxyphenyl)-
2-(4-sulfo-phenyl)-2H-tetrazolium, is converted to a formazan
product that is soluble in tissue culture medium and quanti-
fied by its absorbance at 492nm. The cell number was propor-
tional to MTS dye conversion within the range used in these
experiments.
Migration assay
Analysis of HUVEC migration was performed using the Angio-
genesis Endothelial Cell Migration Kit (BD BioCoat, BD Bioscience,
San Jose, CA, USA). The 5 10
4 HUVEC cells per well were seeded
into the upper chamber of the migration plate insert in migration
media (MCDB 131, 1% FCS and 5IUml
 1 heparin). The lower
chambers contained 750mlo f1 0 n g m l
 1 vegf121. After 22h incu-
bation at 371C, the insert membranes were stained with 4mgml
 1
Calcein AM (Molecular Probes, Invitrogen, Paisley, UK) in Hanks
Balanced Salt Solution for 90min. Fluorescence on the underside of
the membrane was measured at excitation/emission wavelengths of
485 out of 530nm. Images were taken using a Zeiss Axiovert 135
microscope with an Axiocam digital camera at 10  magnification.
Cell cycle analysis
The 1500 HUVEC cells were seeded on to 0.1% gelatine coated
well of a 96-well plate in replicates of eight and incubated at
371C/5% CO2 overnight to adhere. The following day and at
subsequent 24-h intervals, the media was replaced with media
containing 50mM dexrazoxane. At the end of the time course,
media was carefully removed by pipette from all wells and cells
fixed in 85% ice-cold ethanol. This was later removed by pipette
and cells were carefully washed with PBS, which was again
carefully removed by pipette. Cell were incubated in the dark
at 371C for 15mins post-RNase A treatment and made perme-
able with triton X before staining with PI. The 96-well plates
were subsequently scanned using the Acumen
eX3 machine
(TTP LabTech, Melbourn, Royston, UK).
Rat aortic ring assay
Thoracic aortas were harvested from 6- to 8-week-old rats on the
morning of the assay. Matrigel that had been thawed at 41C
overnight was diluted 1:1 with PBS. A measure of 110ml was
then aliquoted per well into a 48-well plate and the plate was
incubated at 371C for 30min to allow the matrigel to set. The
aorta was rinsed in endothelial cell medium and any fibro-
adipose tissue was removed. The aorta was cut into 1–1.5mm
rings using a scalpel blade. The aortic rings were placed on top
of the matrigel in the centre of the well, a further 40mlo f
matrigel was added to hold the aorta in place, and the plate was
returned to the incubator for a further 30min. Growth medium
was then added carefully to a volume of 200ml per well. Drug
was added 24h later and the extent of angiogenesis was assessed
5–6 days later.
Mouse sponge assay
Sterile 8-mm polyurethane sponge discs were inserted under the
dorsal skin of anaesthetised black C57 female mice. Dexrazoxane
(30mgkg
 1) with bFGF (5mgkg
 1) in 0.5% carboxymethyl-
cellulose in saline (carrier solution) was injected into the sponges
on days 1, 3, 5, 7, 9, 11, 13, 15 and 17 after sponge implantation.
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solution alone. A second experiment involved injection of
dexrazoxane (30mgkg
 1) into the tail vein on days 2, 6, 10, 14
and 18 preceded by injection of bFGF (5mgkg
 1) into the sponge
on days 1, 5, 9, 13 and 17 after sponge implantation. Mice
were sacrificed on day 21, and sponges with surrounding tissue
were excised and fixed in 3.5% paraformaldehyde. All in vivo
experiments were performed in accord with British Home Office
license number PPL 70/4949. All animal experiments were
conducted at Clare Hall animal laboratories, Cancer Research UK
and all procedures were within local institute and national ethical
guidelines and were in compliance with the United Kingdom
coordinating committee on cancer research guidelines for the
welfare of animals in experimental neoplasia.
Angiogenesis pathway arrays
Nitrocellulose membrane gene arrays (GEArray Kit, Super Array
Inc, Bethesda, MD, USA) were used to determine the
effect of dexrazoxane on the regulation of genes involved
in angiogenesis following manufacturer’s instructions. Briefly,
32P-labelled cDNA probes were synthesised from total RNA
from untreated HDMEC and from HDMEC that had been
treated with 50mM Dexrazoxane for 24h. The cDNA probes were
hybridised to gene-specific cDNA fragments spotted on the
membranes. The relative expression levels of the genes on the
array were determined using a phosphorimager and quantitation
software.
Western blot analysis
After treatment with Dexrazoxane or THBS-1 siRNA, aliquots
of the medium were collected and the cells were washed with PBS
and lysed in lysis buffer to obtain total protein extract. Western
blotting was performed using 10mg of whole cell lysates and
antibodies to THBS-1 (Neomarkers, MA, USA). Immunodetection
of b-tubulin and MCM7 were used as loading controls.
Transfections with siRNA
A measure of 10
6 HUVECs were seeded on a 0.1% gelatine
coated 10cm plate the day before transfection. siRNA duplexes
g e n e r a t e dw e r eT H B S - 1s i R N A 1( 5 0-GGAGTTCAGTACAGAAATA-30),
THBS-1 siRNA 2 (50-GTACAGAAATAACGAGGAA-30) and nega-
tive control duplex (Eurogentec, Hampshire, UK). Transfection of
HUVEC was carried out using 50nmoll
 1 of siRNA duplexes with
0.3% lipofectamine RNAi Max in optiMEM (Invitrogen, Paisley,
UK). Cells were incubated for 5h at 371C/5% CO2 then the mix was
replaced with medium without antibiotics. At 24 and 48h
posttransfection, knockdown was assessed by RT–PCR, real-time
PCR and western blot.
RT–PCR
Total RNA was extracted from HUVEC using the RNeasy mini kit
(Qiagen, Crawley, West Sussex, UK) according to the manufac-
turer’s protocol. Complementary DNA was prepared using 1mgo f
total RNA and the random priming High-Capacity cDNA Archive
kit (Applied Biosystems, Foster City, CA, USA) according to the
manufacturer’s protocol. The primers THBS-1 mRNA Forward
(50-TTGTCTTTGGAACCACACCA-30) and THBS-1 mRNA Reverse
(50-CTGGACAGCTCATCACAGGA-30) were used at 2.5pmol with
12.5ml of 2xGoTaq green master mix (Promega, Madison, WI,
USA). Reaction conditions were 951C for 5min; 951C for 45s, 601C
for 1min, 721C for 2min; repeated for 30 cycles; 721C for 10min.
Agarose gel electrophoresis gave rise to a 187-bp product when ran
on a 2% agarose gel according to standard protocols.
Real-time PCR
RNA and cDNA were prepared as above and reaction conditions
optimised for the Rotor-Gene 3000 real-time DNA analysis system
(Corbett Research, Sydney, Australia) to obtain the best amplifi-
cation kinetics. The 25-ml reaction mix contained 12.5m of 2 
Sensimix, 1mlo f1 0 mM Sense primer, 1mlo f1 0 mM anti-sense
primer and 0.25ml of 10M probe, with cDNA dilution replicates of
1:10, 1:100 and 1:1000; water was used as a no template control.
Cycling conditions were 951C for 10mins followed by 40 cycles of
951C for 10s, 581C for 15s, 721C for 15s, 821C for 15s. Standard
curve analysis was performed to obtain relative expression levels
for THBS-1 and the housekeeping gene b-actin to which THBS-1
expression was normalised. The cycle threshold was determined
from a curve generated from a plot of cycle number vs fluorescence
with a manual threshold set above the background fluorescence
of the no template control. The dCT method was used to calculate
relative gene expression levels as per protocol by applied bio-
sytems. The levels of expression of the interferon (INF) response
genes, IGS 20 and OAS I were determined as described after siRNA
treatment.
Data analysis
All statistical analyses (t-tests and ANOVAs) were performed using
R and MS Excel functions.
RESULTS
Effect of dexrazoxane on endothelial cell behaviour in vitro
The effect of dexrazoxane on endothelial cell proliferation in vitro
was examined using HUVEC and HDMEC isolates. Increasing
doses of dexrazoxane was found to cause a statistically significant
(P-value o0.001) decrease in cell proliferation (Figure 1A) with
HDMEC being somewhat more sensitive to dexrazoxane than
HUVEC (HUVEC IC50¼71mM; HDMEC IC50¼52mM). The extent
of the growth inhibition of dexrazoxane was determined in both
HUVEC and HDMEC by treating with a single dose of 50mM and
then counting cell numbers on days 3, 4 and 5 after treatment
(Figure 1B). It was found that 50mM dexrazoxane caused growth
inhibition of HDMEC and HUVEC for up to 5 days (P-value
o0.001). Concurrent with this inhibition, increasing doses of
dexraxoxane caused an accumulation of cells in the G2M phase
of the cell cycle (P-value o0.001), peaking at around 50mM
(Figure 1C).
In contrast to the effect on cell proliferation, dexrazoxane was
found to have no effect on VEGF stimulated cell migration
(Figure 1D). Daily dosing with dexrazoxane (50mM) was found to
almost completely inhibit sprouting from aortic rings (Figure 1E,
P-value o0.001). If the medium was changed to dexrazoxane-
free medium at any time for up to 8 days after seeding the
ring, then sprouting occurred showing that dexrazoxane was
having a specific growth inhibitory effect rather than simply a
cytotoxic one.
Effect of dexrazoxane on in vivo angiogenesis
The effect of dexrazoxane in vivo was determined using the mouse
sponge assay (Figure 2). Two dosing protocols were tested. The
drug was either injected directly into the sponge (Figure 2A) or
into the tail vein (Figure 2B). Injection of dexrazoxane into
the sponge was found to result in lower overall vessel numbers
(P-value o0.01), an absence of large vessel and lower cell density
when compared with injection of bFGF alone. A similar result was
obtained when dexrazoxane was injected into the tail vein
(Figure 2B, P-value o0.01).
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Arrays of genes involved in processes relating to angiogenesis were
used to screen for differential gene expression after treatment of
endothelial cells with 50mM dexrazoxane. Of most interest in view
of its known anti-angiogenic activity was a 3.7-fold upregulation of
THBS-1 expression. To confirm this result, cells were treated for 2,
5, 9 and 24h with 50mM dexrazoxane, followed by western blotting
of the total cell lysate to measure bound THBS-1 protein and the
medium to measure secreted THBS-1 protein (Figure 3A).
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Figure 1 Effect of dexrazoxane on angiogenesis in vitro.( A) Effect of Dexrazoxane on cell proliferation in endothelial cells. Cell proliferation was
measured using the MTS assay 3 days after treatment of HDMEC (–’–) and HUVEC (E) with Dexrazoxane. A one-way ANOVA showed that
increasing the concentration of Dexrazoxane statistically significantly reduced cell proliferation (***P-value o0.001) in both HUVECs and HDMECs.
(B) Effect of Dexrazoxane on endothelial cell growth over 5 days. Cell numbers were counted on days 3, 4 and 5 after a single dose of 50mM Dexrazoxane.
The treatment groups were HUVEC control (’), HUVEC treated with 50mM Dexrazoxane ( ), HDMEC control ( ) and HDMEC treated with 50mM
Dexrazoxane (&). Statistical significance of Dexrazoxane treatment vs control was determined using a t-test, indicated by *** (P-value o0.001) in the
figure. Results show that Dexrazoxane treatment significantly reduced the number of cells. (C) Effect of increasing doses of dexrazoxane on the number of
HUVEC in G2M phase of cell cycle. A one-way ANOVA shows that increasing the concentration of dexrazoxane statistically significantly increases the
number of cells in G2-M phase with a P-value o0.001 (***). (D) Effect of dexrazoxane on endothelial cell migration. The effect of 50mM dexrazoxane on
VEGF stimulated HUVEC migration was tested vs a control. Using a t-test, no statistical significance was found between the VEGF alone and
VEGFþDexrazoxane-treated migration of cells. However, in contrast, significant P-values of o0.001 (***) were found comparing both of these to
the untreated control cell migration. (E) Effect of dexrazoxane on the aortic ring assay. Aortic ring sprouting was scored on a scale of 0 (no sprouts), 1 (a few
sprouts), 2 (intermediate sprouting), 3 (substantial sprouting), 4 (complete sprouting). The sprouting from each ring was assessed by two independent
observers and the inter-observer variability was found to be o0.001. A 50-mM dose of Dexrazoxane had a statistically significant effect in reducing the
sprouting index of the aortic ring (t-test, P-value o0.001).
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50mM dexrazoxane and continued to increase for up to 24h after
drug treatment. The levels of secreted THBS-1 increased sharply
2h after treatment and showed a plateau when measured by
western blotting. This result was confirmed using a human THBS-1
ELISA (Figure 3B). When measured by ELISA, THBS-1 secretion
increases for up to 5h after dexrazoxane treatment and then
remained steady for up to 24h.
We investigated whether THBS-2, which is also anti-angiogenic,
could mediate the THBS-1 insensitive inhibition. Analysis of
HUVEC mRNA and protein lysates showed that they do not
express THBS-2 (data not shown). To determine the contribution
of THBS-1 secretion towards dexrazoxane-mediated anti-angio-
genesis, THBS-1-specific siRNAs were designed. Western blotting
of HUVEC lysates showed that THBS-1 protein was reduced at
24 and 48h posttreatment with siRNA compared with controls
(Figure 4A). RT–PCR of RNA extracted from HUVEC treated
with THBS-1 siRNAs showed downregulation of THBS-1 using
two specific siRNA duplexes (data not shown). This was confirmed
using real-time RT–PCR and showed a 95% knockdown at 24h
and 82% knockdown at 48h posttransfection with 50nM siRNA
duplex 1 (Figure 4B). This result was sustained on titration
down to 12nM siRNA (data not shown). Levels of THBS-1 started
to return to baseline both at the RNA and protein level from
72h posttransfection with siRNA (data not shown). Introduction
of siRNA into cells can give artifactual results attributable to
induction of INF secretion from the transfected cell (the so-called
INF response) (Reynolds et al, 2006). To rule out the possibility
of an INF response being generated by siRNA duplexes, the
INF response genes ISG20 and OASI were examined by real-
time RT–PCR post-siRNA transfection. Duplex 1 at a concentra-
tion of 50nmoll
 1 failed to illicit an INF response and so this
duplex was taken forward in subsequent experiments (Figure 4C
and D).
To determine the contribution of THBS-1 secretion towards the
inhibitory effect of dexrazoxane on angiogenesis (or the anti-
angiogenic activity of dexrazoxane), MTS assays were carried
out along with real-time RT–PCR after THBS-1 knockdown
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Figure 2 Effect of dexrazoxane in vivo. Effect of dexrazoxane on angiogenesis in vivo, using the mouse sponge assay. (A) The number of vessels per unit
area of sponge was counted after injection of carrier solution only, bFGF only and bFGF with 50mM dexrazoxane. The top left panel shows a typical example
of a sponge injected with bFGF alone, whereas the bottom left panel shows a typical example of a sponge injected with bFGF with dexrazoxane. (B) The
number of vessels per unit area of sponge was counted after injection of 50mM dexrazoxane into the tail vein on the day after injection of bFGF directly into
the sponge. Both sponge assays produced a statistical significant difference between carrier solution control vs bFGF (P-value o0.01) and bFGF vs bFGF with
dexrazoxane. No significant difference was found between carrier solution control vs bFGF with dexrazoxane.
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sand treatment with dexrazoxane. This revealed that 5 days post-
siRNA transfection and dexrazoxane treatment of HUVEC,
there was a 40% decrease in cell proliferation, which was reduced
to a 20% decrease after THBS-1 knockdown. However, real-time
RT–PCR analysis showed that the level of THBS-1 knockdown
at this time point was only 57% compared with controls
(Figure 5B). To achieve a greater knockdown, HUVEC were
treated with 50nM THBS-1-specific siRNA and received a further
treatment 72h after the initial transfection when the levels of
THBS-1 start to rise. They were further treated with 50mM
dexrazoxane at 24-h intervals for 7 days. At 5 and 6 days
posttreatment of HUVEC, there was now a 27.3% decrease and
51.6% decrease, respectively, in cell proliferation compared with
controls, an effect which was completely ameliorated by treatment
with THBS-1 siRNA (Figure 5C). Thus, knockdown of THBS-1 in
dexrazoxane-treated HUVEC completely blocked the effect of
the drug on cell proliferation. Levels of THBS-1 knockdown
were quantified over the time course by real-time RT–PCR and
showed a knockdown of THBS-1 at the RNA level at days 5 and 6
of 96% and 93%, respectively (Figure 5D).
Dexrazoxane increased the number of cells in G2M, presu-
mably by a G2M block. This effect was largely reversed by THBS-1
knockdown, supporting the cell proliferation work (Figure 5E).
DISCUSSION
Early studies with razoxane showed that it has anti-metastatic
and putative blood vessel normalisation properties (Hellmann
and Burrage, 1969) and it is possible that it could also have
anti-angiogenic activity, although the latter has never been
formally shown. We have now performed in vitro and in vivo
studies to show that dexrazoxane is anti-angiogenic and that this
action is mediated through upregulation of THBS-1. Dexrazoxane
showed clear effects on the vasculature, for example, in the
rodent subcutaneous sponge assay dexrazoxane was able to
reduce bFGF-induced angiogenesis after direct injection into the
sponge or injection into the tail vein with the FGF injected into
the sponge.
Dexrazoxane is metabolised in vivo to its one ring opened
hydrolysis product, ADR-925, which has a structure similar to
that of EDTA (Buss and Hasinoff, 1997). ADR-925 is detectable
within 5min of intravenous administration of dexrazoxane to
rats, suggesting that dexrazoxane is rapidly metabolised in vivo
(Schroeder and Hasinoff, 2002). The hydrolysis products of
dexrazoxane do not inhibit topo II, unlike dexrazoxane itself
(Hasinoff et al, 1995). High millimolar concentrations of dexra-
zoxane hydrolysis products are required in vitro for cytotoxicity
compared with micromolar concentrations for the parent com-
pound (Hasinoff et al, 1995). Therefore, it seems unlikely that
the systemic anti-angiogenic effects of dexrazoxane in the rodent
sponge assay are due to topo II inhibition by dexrazoxane.
By use of microarray, we found that THBS-1 is markedly
upregulated in endothelial cells exposed to dexrazoxane. The
increase in mRNA expression correlated with a corresponding
increase in THBS-1 protein expression and THBS-1 protein
secretion for at least 24h after drug treatment. To determine
whether the observed anti-proliferative properties of dexra-
zoxane on endothelial cells were due to topo II or increased
THBS-1 secretion, we used siRNA to target THBS-1 mRNA in
HDMEC and HUVEC. Cells unable to express THBS-1 were not
growth inhibited by dexrazoxane consistent with THBS-1 upregu-
lation being a part of the anti-angiogenic mechanism of action
of dexrazoxane.
Recent research has suggested that THBS-1 could be a mediator
of the anti-angiogenic effects of low-dose metronomic chemo-
therapy (Bocci et al, 2003). Unlike conventional cancer chemo-
therapy, low-dose metronomic chemotherapy targets dividing
endothelial cells in the newly forming blood vessels within tumours
rather than the surrounding genetically unstable tumour cells
(Browder et al, 2000). This has been called anti-angiogenic
chemotherapy or metronomic dosing (Hanahan et al, 2000). The
advantages of this approach are that the lowered drug dose gives
fewer side effects, whilst significantly delaying the onset of drug
resistance and improving the efficacy and durability of chemo-
therapy (Browder et al, 2000; Klement et al, 2000; Colleoni et al,
2002). The possible selective nature of this type of chemotherapy
towards endothelial cells was reinforced when it was found that
exposure to protracted low-dose chemotherapy in vitro and in vivo
resulted in a marked induction of THBS-1 (Bocci et al, 2003). In our
study, we compared the effect of local injection into the sponge with
systemic injection into the tail vein on the blood vessel density of
the sponge. The protocol used for the local injection experiment
resembled that of a metronomic dosing schedule. The maximum
tolerated dose (MTD) of dexrazoxane in mice is 250mgkg
 1,7
times higher than our dose of 35mgkg
 1, which was given every
second day for 17 days. We propose, therefore, that in small regular
doses, administration of dexrazoxane potently inhibits angiogenesis.
Thrombospondins are secreted calcium binding glycoproteins
implicated in a number of cellular processes including wound
healing and cancer (Tuszynski et al, 1987a,b; Asch and Nachman,
1989; Sargiannidou et al, 2001).
The family has five members, two of which, THBS-1 and THBS-2
have been shown to play a role in platelet aggregation, wound
healing and angiogenesis through their N-terminal properdin type
I repeats (Volpert et al, 1995; Bonnefoy et al, 2008). Expression of
THBS-1 has been shown to be up-regulated by hypoxia and heat
shock. In contrast, a number of growth factors including TNFa,
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Figure 3 Upregulation of thrombospondin-1 by dexrazoxane in vitro.
(A) Western blotting of HUVEC whole cell lysate and medium after
treatment with 50mM Dexrazoxane for 2, 5, 9 and 24h displayed an
increase in THBS-1 protein expression over the time course. (B) This result
was confirmed by ELISA using conditioned medium of cells treated with
Dexrazoxane at different time points.
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sIL-1b and a variety of transforming oncogenes such as c-jun,
reduce expression (Adams, 1995; Watnick et al, 2003). THBS-1 is
induced by p53 and binds to CD47, CD36, integrins and heparin
sulphate proteoglycans (Sid et al, 2004) in turn inhibiting the
effects of VEGF, bFGF and IL-8 (Dameron et al, 1994a,b). The
endothelial cell apoptotic activity of THBS-1 is mediated through
interaction with the Fas/Fas ligand, caspase-3 activation and
FAK fragmentation (Volpert et al, 2002).
There has been significant interest in THBS-1 mimetics as anti-
angiogenics, as it is not feasible to administer THBS-1 itself due to
its large size. However, peptide mimetics have suffered severe
in vivo stability problems (Giavazzi and Taraboletti, 1999). The
outcome of a phase II study investigating the efficacy of a THBS-1
mimetic (ABT-510) in soft tissue sarcoma showed safety but no
compelling evidence for use as a single agent. The authors suggest
that further validation in combination with current chemotherapy
regimes, such as 5-Flurouracil (5-FU) may be of benefit. The
proposed mode of action is to block binding of THBS-1 to
endothelial cells, inducing expression of Fas ligand and preventing
VEGF- and bFGF-induced migration (Baker et al, 2008).
A number of chemotherapeutic agents such as 5-FU and
trastuzumab up-regulate THBS-1, with 1moll
 1 of 5-FU up-
regulating the level of THBS-1 three-fold in KM12C human colon
carcinoma cells and two-fold in HUVEC and human colon
adenocarcinoma LOVO cells (Zhao et al, 2008). The transcription
factor Sp-1 has been shown to be important for the EGF-induced
THBS-1 expression (Okamoto et al, 2002). Cytotoxic drugs
have been shown to up-regulate members of the MAPK family
(Srivastava et al, 1999) and Zhao et al suggest that p38 MAPK
signalling functions in 5-FU, trastuzumab and TGFb1 regulation
of Egr-1and THBS-1.
This work is of particular significance with the advent of
anti-vascular endothelial growth factor antibody Bevazucimab
(Avastin, Gentec, South Francisco, CA, USA) and the realisation
that its mechanism of anti-tumour activity is primarily due to
normalisation of tumour vessels (Willett et al, 2004). Identification
of the mechanism of anti-angiogenic action now identifies
thromospondin-1 as a potential surrogate of response and investi-
gation and monitoring of THBS-1-1 levels may be of benefit in
future clinical trials with dexrazoxane. Dexrazoxane is a very
inexpensive but potent anti-angiogenic agent. In conclusion, our
results demonstrate that dexrazoxane when administered in small
regular doses acts in vivo as a potent anti-angiogenic agent and this
action is at least in part mediated by an upregulation of THBS-1.
1.2 *** ***
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Figure 4 Downregulation of THBS-1 by siRNA. (A) Western blot showing the downregulation of THBS-1 in HUVEC at 24 and 48h posttransfection
with THBS-1 targeting siRNA. (B) Real-time PCR showing the downregulation (P-value o0.001) of THBS-1 in HUVEC, targeted by THBS-1 siRNA at 24
and 48h posttransfection. (C and D) Real-time PCR showing no significant upregulation of the interferon response genes ISG 20 and OAS I in HUVEC
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Figure 5 Effect of downregulation of THBS-1 on cell proliferation after treatment with dexrazoxane. (A) MTT assay showing cell proliferation 5 days
posttransfection with THBS-1 siRNA and dose–response to 50mM dexrazoxane given at 24-h intervals. The results show that the anti-proliferative effect of
dexrazoxane is partially mediated by THBS-1 as its knockdown shows significant increase in cell proliferation (P-value o0.01 at 25mM through to 100mM)a sc o m p a r e d
with the untransfected and negative controls. (B) Real-time PCR showing statistically significant downregulation (P-value o0.01) of THBS-1 in HUVEC treated with
THBS-1 siRNA at 5 days posttransfection. Although still significantly differentially expressed (knockeddown) at 5 days posttransfection, the percentage knockdown has
decreased by 38% as compared with 24h. (C) MTT assay showing cell proliferation 3–7 days posttransfection with THBS-1 siRNA at day 0 and again at day 3 with
concurrent treatment with 50mM dexrazoxane at 24-h intervals. (D) Real-time PCR showing downregulation of THBS-1 in HUVEC from 3 to 7 days with transfection
with THBS-1 siRNA taking place at day 0 and again at day 3. The downregulation of THBS-1 was statistically significant at all time points, P-value o0.001. (E)
Proportion of HUVEC in G2M phase of cell cycle 5 days posttransfection with THBS-1 siRNA and treatment with 50mM dexrazoxane at 24-h intervals. Dexrazoxane
treated cells alone vs the control showed statistical difference (P-value 40.01) in the number of cells in G2M phase. This effect was reversed with THBS-1 knockdown.
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Statement of translational relevance
This work describes a novel and potent anti-angiogenic activity of
the drug dexrazoxane and shows that this activity is due to
induction of thrombospondin-1. The work is of importance for the
identification of compounds with anti-angiogenic activity and
the development of future anti-angiogenic therapies.
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